METTL3 inhibitor compounds
Compounds targeting METTL3 activity address the lack of effective inhibitors for diseases associated with this enzyme, offering therapeutic benefits by inhibiting its function in various disorders.
JP7762957B2Active Publication Date: 2025-10-31STORM THERAPEUTICS LIMITED
9 Cites 0 Cited by
Patent Information
- Application Number
- JP2021560410
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-12-20
- Filing Date
- 2020-04-03
- Publication Date
- 2025-10-31
- Estimated Expiration
- 2040-04-03
AI Technical Summary
Technical Problem
Current treatments for diseases associated with METTL3 activity, such as cancer, autoimmune, neurological, infectious, and inflammatory disorders, lack effective inhibitors that target this enzyme to modulate its activity and provide therapeutic benefits.
Method used
Development of compounds that inhibit METTL3 activity, which can be used in pharmaceutical compositions to treat these diseases by inhibiting the enzyme's function.
Benefits of technology
The compounds effectively inhibit METTL3 activity, leading to reduced proliferation, metastasis, and apoptosis in cancer cells, and provide therapeutic benefits for autoimmune, neurological, infectious, and inflammatory diseases.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to compounds of formula (I): XYZ(I), where X, Y and Z are as defined herein, as inhibitors of METTL3 (N6-adenosine methyltransferase 70 kDa subunit) enzyme activity. The present invention also relates to processes for the preparation of these compounds, pharmaceutical compositions containing them and their use in the treatment of proliferative disorders such as cancer and autoimmune diseases and other diseases in which METTL3 activity is implicated.
Need to check novelty before this filing date? Find Prior Art